Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid packing contributes to the confinement of caveolae to the plasma membrane.

eLife·2026
Same author

METTL3 regulates exocytosis independently of m<sup>6</sup>A.

Science advances·2026
Same author

Salmonella lipopolysaccharide-containing supported lipid bilayers as platforms to study bacteriophage interactions.

FEBS letters·2026
Same author

Protocol for total internal reflection fluorescence microscopy image preprocessing and radial analysis of LFA-1 in T cell immune synapses.

STAR protocols·2026
Same author

Advancing physical virology through multiscale approaches-Insights from the 2025 FEBS|EMBO lecture course 'Physical Virology: across length scales'.

FEBS letters·2026
Same author

Multivalency influences virus dynamics at the glycocalyx: A study of glycosaminoglycan binding in HPV16 entry.

Biophysical journal·2026
Same journal

Dynamics of Circulating Follicular Helper and Regulatory T-Cell Memory Induced by mRNA, Inactivated, and Live-Attenuated Vaccines.

Journal of immunology research·2026
Same journal

A State of the Art Review on the Recalcitrant Candidiasis as a Clue of Inborn Errors of Immunity in Newborns.

Journal of immunology research·2026
Same journal

The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value.

Journal of immunology research·2026
Same journal

Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients.

Journal of immunology research·2026
Same journal

Anti-MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B-Cell Population.

Journal of immunology research·2026
Same journal

Immunophenotypic Profiling of Lymphocyte Subsets in Children and Adolescents With Acute Lymphoblastic Leukaemia: Immune Dysregulation Before and After Remission.

Journal of immunology research·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.1K

Mucosal Vaccine Development Based on Liposome Technology.

Valentina Bernasconi1, Karin Norling2, Marta Bally2

  • 1Mucosal Immunobiology and Vaccine Center (MIVAC), Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.

Journal of Immunology Research
|January 28, 2017
PubMed
Summary
This summary is machine-generated.

Developing effective mucosal vaccines requires overcoming challenges in antigen dose and adjuvant use. Liposome nanoparticle technology offers a promising solution for next-generation mucosal vaccines delivered orally or via respiratory and genital tracts.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion&#45;Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 8, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.1K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion&#45;Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

1.3K

Area of Science:

  • Vaccinology
  • Immunology
  • Nanotechnology

Background:

  • Mucosal vaccines offer targeted immune protection at pathogen entry points, addressing a growing demand for oral, respiratory, and genital tract administration.
  • Current mucosal vaccines face limitations including low efficacy of subcomponent vaccines, need for adjuvants, and large antigen doses, despite advancements in understanding mucosal immunity.

Purpose of the Study:

  • To explore the potential of nanoparticle formulations, specifically liposomes, for developing next-generation mucosal vaccines.
  • To address the challenges of antigen dose and adjuvant requirement in mucosal vaccine development.

Main Methods:

  • Review of recent advancements in nanoparticle technology, focusing on liposome formulations for mucosal vaccines.
  • Discussion of the integration of mucosal adjuvants with nanoparticle delivery systems.

Main Results:

  • Liposome technology is well-suited for combining protein antigens and adjuvants into a single, effective mucosal vaccine formulation.
  • Nanoparticle-based mucosal vaccines show promise in overcoming dose limitations and enhancing immunogenicity.

Conclusions:

  • Liposome-based nanoparticle formulations represent a significant advancement in mucosal vaccine development.
  • This approach holds strong promise for the creation of effective next-generation mucosal vaccines with improved safety and stability.